Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

Inclusion Criteria: * Healthy volunteers between 8 - 12 months old; * Proven legal identity; * Written consent of the guardian(s) of the volunteer Exclusion Criteria: * Received mumps vaccine or vaccine containing mumps virus; * History of mumps; * Axillary temperature \> 37.4 °C; * History of allergy to any vaccine or vaccine ingredient; * History of serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; * Autoimmune disease or immunodeficiency or immunosuppression; * Congenital malformation, genetic defects, severe malnutrition; * Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders; * Severe chronic diseases (e.g., severe cardiovascular disease, liver and kidney disease beyond the control of drugs, or cancer) * Severe neurological disorders (epilepsy, seizures or convulsions) or psychosis; * History of thyroidectomy, absence of spleen, functional absence of spleen, and any condition resulting from absence of spleen or splenectomy; * Receipt of any of the following products: 1. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry; 2. Any live attenuated vaccine within 28 days prior to study entry; 3. Any other investigational medicine(s) or vaccine within 30 days prior to study entry; 4. Blood product within 3 months prior to study entry; 5. Any immunosuppressant, cytotoxic medicine, or oral corticosteroids; 6. Any of the acute disease or attack of the chronic disease within 7 days; 7. Pregnant in cohabitants or congenital immune diseases; 8. Based on the judgment of investigator(s), there was any condition indicating that the subject should be excluded